Lv5
1350 积分 2020-08-12 加入
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
1天前
已完结
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
1天前
待确认
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
2天前
已完结
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
1个月前
已完结
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
1个月前
已完结
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse
3个月前
已完结
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML
3个月前
已完结
MRD intervention in AML: A new therapeutic horizon
3个月前
已完结
A clinical guide to TP53 mutations in myeloid neoplasms
3个月前
已完结
TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
3个月前
已完结
皖公网安备34019202002308
